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Abstract Sweet tasting proteins interact with the same recep-
tor that binds small molecular weight sweeteners, the T1R2^
T1R3 G-protein coupled receptor, but the key groups on the
protein surface responsible for the biological activity have not
yet been identi¢ed. I propose that sweet proteins, contrary to
small ligands, do not bind to the ‘glutamate-like’ pocket but
stabilize the free form II of the T1R2^T1R3 receptor by attach-
ment to a secondary binding site. Docking of brazzein, monellin
and thaumatin with a model of the T1R2^T1R3 sweet taste
receptor shows that the most likely complexes can indeed sta-
bilize the active form of the receptor. * 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Glucophores on sweet proteins
Low-calorie sweeteners are important for persons a¡ected
by diseases linked to the consumption of sugar, e.g. diabetes,
hyperlipemia, caries. Most sweet compounds, including all
popular sweeteners, are small molecular weight compounds
of widely di¡erent chemical nature, but there are also sweet
macromolecules, both synthetic [1] and natural, i.e. sweet pro-
teins [2]. Sweet molecules elicit their taste, in humans and
other mammals, by interacting with the recently discovered
T1R2^T1R3 receptor [3^5]. The sequence of this protein in-
dicates that it is a metabopromic 7 transmembrane G-protein
coupled receptor with a high homology to the mGluR subtype
1 [4]. The structure of the N-terminal part of the mGluR has
been recently determined by X-ray di¡raction and has been
used as a template to build a homodimeric T1R3^T1R3 re-
ceptor model [4]. It is very likely that small molecular weight
sweet molecules occupy a pocket analogous to the glutamate
pockets in the mGluR [5], possibly similar to the active site
models predicted by indirect receptor mapping studies [6^11].
It is more di⁄cult to envisage the same type of interaction
for sweet proteins. If the glucophores on the protein surface
are similar to those that account for the taste of small mole-
cules, it might be possible to identify putative ‘sweet ¢ngers’
that can be accommodated in the cavities of proposed active
site models. However, existing models can hardly explain the
enormous increase in activity in going from small molecular
weight compounds to proteins. For example monellin, one of
the best characterized sweet proteins, is 100 000 times sweeter
than sucrose on a molar basis [12].
The key groups on the protein surface responsible for the
biological activity have not yet been identi¢ed with certainty
for any of the known sweet proteins [13]. Sweet tasting pro-
teins have di¡erent molecular lengths (from the 54 residues of
brazzein to the 202 residues of thaumatin), virtually no se-
quence homology and very little structural homology [14].
It is customary to try to identify corresponding parts of
proteins with the same function by comparing their sequences
or their 3D structures. I ¢nd no sequence homology among
miraculin [15], monellin [16], thaumatin [17], curculin [18],
mabinlin [19] and brazzein [20]. Attempts to ¢nd structural
similarity among the 3D structures of monellin, thaumatin
and brazzein, were made by means of DALI [21], but yielded
only a vague resemblance of three hairpins. Another com-
monly used strategy is to mutate systematically all residues
that are suspected to host potential glucophores or that
have a key structural role. Extensive mutagenesis studies on
monellin [22] and on SCM, one of its single chain mutants
[23], yielded several constructs with substantial loss of activity,
but the residues involved are not localized in a single struc-
tural element that could be considered a suitable ‘sweet ¢n-
ger’. Similarly, point mutations on brazzein show that sweet-
ness determinant sites are located in at least two regions of the
protein surface.
2. The T1R2^T1R3 receptor
The easiest way out of this impasse would be to invoke a
di¡erent receptor for sweet macromolecules with respect to
small molecular weight sweeteners, but this would still leave
completely open the problem of explaining the commonalities
among the sweet proteins. Besides, it has been recently shown
[5] that two of the known sweet proteins, i.e. brazzein and
thaumatin, elicit a response in the human T1R2^T1R3 recep-
tor, similarly to small molecular weight sweeteners.
I want to show that it is possible to reconcile the interaction
of small and macromolecular sweeteners with the same recep-
tor, provided sweet proteins interact with the T1R2^T1R3
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receptor with a di¡erent mechanism with respect to small
molecular weight compounds.
Let us assume that the T1R2^T1R3 receptor, apart from
obvious di¡erences in the active site, shares the general char-
acteristics of the mGluR. The most striking feature of the N-
terminal domain of the mGluR, highlighted by the beautiful
structural work of Kunishima et al. [24,25] is the large con-
formational change induced by glutamate complexation. Ku-
nishima et al. [24] have determined the crystal structures of
the N-terminal ligand-binding region of m1-LBR, the mGluR
subtype 1, both free and complexed with glutamate. m1-LBR
is a £exible homodimer whose ‘active’ and ‘resting’ conforma-
tions are modulated through the dimer interface. Each proto-
mer is composed of two domains, LB1 and LB2, that can
form ‘open’ or ‘closed’ conformations. Ligand binding in-
creases the population of the ‘active’ conformer, i.e. the so-
called ‘closed-open_A’. The ligand-free receptor exists as two
di¡erent structures, free form I (open-open_R), the ‘resting’
conformation with two open protomers and free form II
(closed-open_A), nearly identical to the complexed form.
The mechanism suggested by these structures is that the re-
ceptor is in dynamic equilibrium, and that ligand binding
stabilizes the ‘active’ dimer.
There are thus two ways, in principle, to activate the recep-
tor: the most obvious one is to complexate form I with the
proper ligand (glutamate for the mGluR, aspartame or any
other small molecular weight sweetener for the T1R2-T1R3
receptor) and, secondly, by shifting the equilibrium between
free form I and free form II in favor of free form II. I propose
that sweet proteins interact with the free form II of the T1R2^
T1R3 receptor and stabilize it.
Fig. 1 shows a scheme (adapted from [24]), which explains
how stabilization may result from attachment of a sweet pro-
tein to a secondary binding site on the surface of free form II.
In order to substantiate this hypothesis I have built a het-
erodimeric model of the T1R2^T1R3 receptor using the
SWISS MODEL tool of EXPASY in the oligomeric mode
[26^28] and simulated complexation in silico with representa-
tive models of the three known sweet protein structures by
means of docking calculations with the free form II of the
receptor.
The T1R2^T1R3 model was built using the coordinates of
the free form II of m1-LBR (1ewv.pdb). This is the only
possible template, as judged from a search of databases, but
the homology of both protomers is high enough (s 40%) to
yield a reliable model. The main missing residues in the crystal
structure, from 125 to 153, are located in a region that is not
critical for the conformational transition from free form I to
free form II.
3. Docking
Docking was performed using the program GRAMM in the
low-resolution mode [29,30]. This docking method has been
optimized to circumvent the multiple minima problems and is
best suited to cases in which there is no hint of likely binding
sites. The essential point of this procedure is to reduce protein
structures to digitized images on a 3D grid. Structural ele-
ments smaller than the step of the grid are not present in
the docking, thus allowing tolerance to structural inaccuracies
and making it possible the study of the role of the low-reso-
lution recognition in protein complexes. Tolerance is essential
in a case where at least one of the partners (the receptor
model) is not a high-resolution structure. The search for the
possible external binding site was ¢rst performed with MNEI
(1fa3.pdb), a single chain monellin since in this case the struc-
ture^function relationship has been thoroughly investigated
and it is possible to use a wealth of information from closely
related proteins, i.e. native monellin and another single chain
monellin [14,31].
Among the ¢rst 40 preferred solutions found by GRAMM,
none is on the ‘wrong’ side of the receptor model, i.e. the side
facing the membrane; all of them are in fact on the same side
of the receptor and most of them are centered on a large
cavity of the T1R3 protomer. I selected the best candidates
on the basis of the possibility of inhibiting the conformational
rearrangement that leads to free form I; the most obvious
candidates are those that ‘bridge’ the two protomers (T1R2
and T1R3), possibly inserting crucial residues in the cleft be-
tween them.
The face of MNEI interacting with the receptor includes
most residues previously identi¢ed by mutagenesis and surface
survey experiments [14], particularly the crucial N-terminal
residues (I6, D7, G9) and C-terminal residues, with the puta-
tive sweet ¢nger (63^68) bridging the protomers. It is also very
interesting that the electrostatic potentials of the T1R3 pro-
tomer cavity and MNEI have largely complementary charges,
with a prevalently negative T1R3 cavity and a prevalently
positive MNEI surface.
I selected analogous complexes for brazzein (1brz.pdb) and
thaumatin (1thw.pdb); also in these two cases the preferred
Fig. 1. Cartoon representation of the equilibrium between hypotheti-
cal free form I and free form II (equivalent to the complexed form)
of the T1R2^T1R3 receptor showing possible stabilization from at-
tachment of a sweet protein to a secondary binding site on the sur-
face of free form II. The dark spots in the complex on the upper
right-hand side represent small molecular weight sweeteners in pock-
ets corresponding to the glutamate pockets. The sweet protein is
represented as a darker wedge on the left £ank of free form II, pre-
venting it to revert to form I.
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solutions included several complexes that would prevent the
conformational switch from free form II to free form I. Also
in these cases the surface of interaction of the protein is prev-
alently positive. Fig. 2 shows representative models of the
three complexes.
The proposed mode of interaction of sweet proteins is con-
sistent with the di⁄culty of ¢nding consensus sweet ¢ngers
(i.e. a small structural feature protruding from the surface)
common to the three of them; in fact, with a large interacting
surface, it is easier to explain a stronger binding and it is not
necessary to have high sequence homology (only the shape of
the interacting surface needs to be conserved). Such an inter-
action is consistent with a more e⁄cient and long-lasting sta-
bilization of the activated form of the receptor, with respect to
the conformational transition induced by small sweeteners
entering the cavity analogous to the glutamate pocket.
4. Potential experiments
Can this hypothesis be tested? The most obvious experi-
ment would be to perform an X-ray study of the receptor
complexed with one of the sweet proteins. So far there is no
crystal structure of the receptor itself but the close similarity
with the mGluR suggests that such a structure may be avail-
able in a reasonable time. Then, it ought to be relatively easy
to obtain crystals of a complex with a sweet protein since the
very high sweetening power of sweet proteins implies a large
binding constant. This view is strongly supported by the mod-
el emerging from the docking study, since the interacting area
is very large and with good electrostatic complementarity.
Other experimental approaches that come to mind are com-
petition experiments and £uorescence resonant energy transfer
[32]. In this respect, using the complex of MNEI, it can be
suggested that suitable chromophores could be attached to
residues not directly involved in the interaction, e.g. Lys25
that sits at the bottom of the helix of monellin and Lys127
of the T1R2 protomer of the receptor model that is located at
the beginning of a long helix. Another obvious experiment
could be to predict tasteless functional mutants di¡erent
from those described in [22,23]. For instance, Arg39 of mon-
ellin, that is located on the interacting surface of MNEI, could
be as crucial as Asp7, particularly if one considers the electro-
static complementarity. Additional survey of recent literature
indeed shows that the R39E mutant is devoid of sweet taste
[33]. An interesting residue of MNEI is Tyr65, since it is part
of both the sweet ¢nger and of the interacting surface. Where-
as mutant Y65G (corresponding to YA13G) proved sweet
[22], I foresee, on the basis of electrostatic complementarity,
that Y65D ought to be tasteless.
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